Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET [doxorubicin liposomal] Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2 [human epidermal growth factor receptor 2]-Positive Breast Cancer

Next Previous
Trial Profile

Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET [doxorubicin liposomal] Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2 [human epidermal growth factor receptor 2]-Positive Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Trastuzumab
  • Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Sponsors Cephalon France; Teva Pharmaceutical Industries

    • Most Recent Events

    • 11 Oct 2016 Primary endpoint (Pathological complete response (pCR) in breast, upon histologic examination) has not been met according to the results presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
    • 08 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top